Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Clearly you do NOT follow CHARTS then. In your own words, you are not selling even though the CHARTS indicate you should...
Therefore, your 'credibility' is diminished as you pontificate the 'basics' of trading and charting as a 'standard' for profitable stock trading. Ie. buying low and selling high.
Why don't you make your point by 'following the chart' and showing us all how it makes you a superior investor? Otherwise, you are no better than the 'guessing' we do, right?!
Simply, the SP is the 'market sentiment', nothing more, nothing less, on a company. Sentiment is profoundly negative and has been for a long time. A very long time.
Cytori up nearly 5% today. When ward threw last time PSTI had a 5% move top the upside?....
Must be why the orders wont stop coming in!! This is what happens when you make your bookeeper your top salesman.
Remember the good ole days
Funny one allo.
Still no RMAT designations for PSTI, allo...
CYTX may be a better play in the near term.
NO!vember.
Good one, Scott!
Might as well think of one for December too.
Rocktober
There Is A Reason Pluristem…
Funny, really funny stuff, allo. The IRONY here is rib-busting!
9:10 AM It May Sound Crazy But… Addressing Scalability at the Beginning NOT the End
-Conduct a cost-benefit analysis of the differences between proactive automation for scale and reactive scalability
-Create a manufacturing process that is flexible enough to deliver lean production across pre-clinical and clinical development
-Adopt best-in-class technology to assist in in-house manufacturing rather than outsourcing your production
OMG... REALLY?? The company that just HAD TO make a deal with ThermoFisher to address their woefully ineptitude for anticipating the 'scaling' needs of their own portfolio!?!?!? First it was allo's LONZA speculation and now a super-duper 'partnership' with TF...
"-Adopt best-in-class technology to assist in in-house manufacturing rather than outsourcing your production"[color=red][/color]
SO Rich; you just can make this FDAatt up!
World tour has begun!!!
I hear Europe is beautiful in November. Maybe they will announce the 'Partnership Deal' with LONZA here in Isreal!!
THIS IS THE BIG ONE ! Giddy-Up !
If leadership is waiting on or using a 'partnering conference' to actively engage and execute a partnership strategy, we have MUCH bigger issues.
We already have a 'partnership' with J&J, right? It will be announced today per FDApproved.
FDAtt! (pronounced efdat)
"So far, he and a partner are the only ones working on WideTrial."
By Chris Rauber – Reporter, SFBT
May 31, 2018, 5:24pm
"Late last year, he decided to add something new, augmenting the nonprofit approach by also launching WideTrial Inc., a tiny for-profit based in San Francisco that aims to achieve some of the same ends by sponsoring expanded clinical trials for drug companies testing therapies with the potential to treat or cure diseases like ALS, Alzheimer’s or pancreatic cancer. So far, he and a partner are the only ones working on WideTrial."
https://www.bizjournals.com/sanfrancisco/news/2018/05/31/this-man-proposes-a-win-win-for-patients-pharma.html
2020 and not a day sooner. IMHO.
Total Tea Leaf..Belief....10-18-2018 = PLX-R18 Green Scream Scene !
Operators standing by... What time is the big announcement today?!
Have Yaky & Zami put the most important EAP venture in the company's history into the hands of a 10-month-old clinical trial start-up? Sure looks that way.
Leadership there seems to have passion, but no history of execution with what will be a MISSION CRITICAL safety and efficacy trial for approval of PLX-PAD.
The 2012 debacle over the 'compassionate use' EAP, has left investors leary and short of trust for psti's leadership. Remember the company's announcement by Zami, over the seemingly 'cured' patients, who later passed away?!?!?!
https://www.benzinga.com/news/12/05/2572600/from-earlier-compassionate-use-of-pluristems-plx-cells-saves-the-life-of-a-child-
One would think we might want to select a Tried, True, Proven trial leader to conduct this CRITICAL trial. As zzaat, fda, etal. have stated, these trials are 'high risk' for psti...
IMAGINE... just imagine if 'something' goes wrong with psti being the FIRST customer... IMHO
How Did Those FAKE Investigations
FDAatt ! FDAatt!
The Rosen Law Firm Announces Investigation of Securities Claims Against Pluristem Therapeutics, Inc. --- PSTI
https://www.businesswire.com/news/home/20121220006480/en/Rosen-Law-Firm-Announces-Investigation-Securities-Claims
Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock
https://ca.finance.yahoo.com/news/options-traders-expect-huge-moves-134801088.html
Total Tea Leaf..Belief....10-18-2018 = PLX-R18 Green Scream Scene !
Well, you missed on BARDA, J&J, Janssen, Compounds, EAP, and the list goes on...
FDAatt !
Naw!!! Prognosticating is not your forte!
FDAatt rocketboy !
FDAatt Theme Song !
Companies, Individuals and Organizations...
You left off a couple of important ones, so I took the liberty of updating!!
Re: Auto1 post# 16982
0
Post # of 16986
Companies, Individuals and Organizations Pluristem has fooled (and continues to fool):
PLX-11
United Therapeutics
FDA
NIH (and NIAID)
DOD
European Medicines Agency
Japan’s Pharmaceuticals and Medical Devices Agency
Ministry of Food and Drug Safety (South Korea)
Israeli Ministry of Health
Beth Israel Deaconess Medical Center
Texas A&M University
Indiana University
Case Western University
Duke University
Charité University Hospital
Berlin-Brandenburg Center for Regenerative Therapies
Hadassah Medical Center
Tel Aviv Sourasky Medical Center (Ichilov Hospital)
Fukushima Medical University
Fukushima Global Medical Science Center
CHA Biotech
Thermo Fisher Scientific Inc.
Sosei (Potentially)
Maxim Group (Jason McCarthy)
Seaport Global (Vernon Bernardino)
Edison (Maxim Jacobs)
H.C. Wainwright & Co. (Swayampakula Ramakanth Ph.D.)
B. Riley FBR (George B. Zavoico Ph.D.)
Leader Capital Markets (Israel) (Sabina Podval)
To name a few...
Individuals not fooled by Pluristem:
Auto1
*The link I am responding to is from the comment section of the SEC page. Please share the link where the SEC prosecuted PSTI for these alleged transgressions. Very dishonest post, hence my reply.
Re: Auto1 post# 16982
0
Post # of 16986
Companies, Individuals and Organizations Pluristem has fooled (and continues to fool):
FDA
NIH (and NIAID)
DOD
European Medicines Agency
Japan’s Pharmaceuticals and Medical Devices Agency
Ministry of Food and Drug Safety (South Korea)
Israeli Ministry of Health
Beth Israel Deaconess Medical Center
Texas A&M University
Indiana University
Case Western University
Duke University
Charité University Hospital
Berlin-Brandenburg Center for Regenerative Therapies
Hadassah Medical Center
Tel Aviv Sourasky Medical Center (Ichilov Hospital)
Fukushima Medical University
Fukushima Global Medical Science Center
CHA Biotech
Thermo Fisher Scientific Inc.
Sosei (Potentially)
Maxim Group (Jason McCarthy)
Seaport Global (Vernon Bernardino)
Edison (Maxim Jacobs)
H.C. Wainwright & Co. (Swayampakula Ramakanth Ph.D.)
B. Riley FBR (George B. Zavoico Ph.D.)
Leader Capital Markets (Israel) (Sabina Podval)
To name a few...
Individuals not fooled by Pluristem:
Auto1
*The link I am responding to is from the comment section of the SEC page. Please share the link where the SEC prosecuted PSTI for these alleged transgressions. Very dishonest post, hence my reply.
Have Yaky & Zami put the most important EAP venture in the company's history into the hands of a 10-month-old clinical trial start-up? Sure looks that way.
Leadership there seems to have passion, but no history of execution with what will be a MISSION CRITICAL safety and efficacy trial for approval of PLX-PAD.
The 2012 debacle over the 'compassionate use' EAP, has left investors leary and short of trust for psti's leadership. Remember the company's announcement by Zami, grandstanding and bs over the seemingly 'cured' patients then, who later passed away?!?!?!
https://www.benzinga.com/news/12/05/2572600/from-earlier-compassionate-use-of-pluristems-plx-cells-saves-the-life-of-a-child-
One would think we might want to select a Tried, True, Proven trial leader to conduct this CRITICAL trial. As zzaat, fda, etal. have stated, these trials are 'high risk' for psti...
"...So far, he and a partner are the only ones working on WideTrial." - May 31, 2018, SFBT https://www.bizjournals.com/sanfrancisco/news/2018/05/31/this-man-proposes-a-win-win-for-patients-pharma.html
IMAGINE... just imagine if 'something' goes wrong with psti being the FIRST customer?!?!?
Pluristem Reports Strong Results of Stroke Drug Test
https://www.haaretz.com/1.4967011
criminal Israeli U.S. penny stock pump and dump called 'Pluristem'
https://www.sec.gov/comments/s7-19-07/s71907-363.htm
Investor Investigation Over Potential Securities Laws Violations Announced
shareholdersfoundation.com/caseinvestigation/pluristem-therapeutics-inc-nasdaqpsti-investor-investigation-over-potential-secure
Pluristem Therapeutics Current Ratio 2006-2018 | PSTI
Here's some charts for you... Looks like another dilution event shaping up in the near-term?!
https://www.macrotrends.net/stocks/charts/PSTI/pluristem-therapeutics/current-ratio
Engrafted cells increased 2 to 4 times using Pluristem Ltd.'s adjuvant cell therapy product known as PLX-I.
Pluristem Life Systems, Inc. (Pluristem) is engaged in the business of the development of the stem cell production technology and the commercialization of cell therapy products. On May 5, 2003, the Company entered into a license agreement with the Weizmann Institute of Science and the Technion-Israel Institute of Technology to acquire a license for a stem cell production technology. On July 5, 2006, the Company's subsidiary, Pluristem Ltd., conducted a preclinical study of bone marrow transplants, in which engrafted cells increased 2 to 4 times using Pluristem Ltd.'s adjuvant cell therapy product known as PLX-I. The Company is in the process of seeking the regulatory approval from the United States Food and Drug Administration (FDA) and in the European Union for its PluriX Bioreactor system.
Dr. Shai Meretzki
2002-2008 Founder, CTO and CEO - Pluristem Life System, MATAM Advanced Technology Park, Haifa, Israel
Pluristem Therapeutics Inc. (NASDAQ: PSTI; DAX: PJT) is a bio-therapeutics company dedicated to the commercialization of allogeneic (non-personalized) cell therapy products for the treatment of a variety of severe degenerative, ischemic and autoimmune disorders where current therapies are unavailable or inadequate.
PLX-PAD, Pluristem’s first product, targets an annual $4 billion market and is intended to treat patients suffering from the critical stage of peripheral artery disease (PAD), manifesting as limb ischemia. PAD affects millions of patients whose symptoms stem from a decrease in blood supply primarily to the lower extremities. PAD is aggravated by conditions such as atherosclerosis, diabetes and smoking. PLX-PAD targets those patients where traditional medical and surgical therapies have not helped and are potentially facing continued symptoms or amputation. In animal studies PLX-PAD has shown to significantly increase the number of new blood vessels (angiogenesis) and blood flow in the involved extremity. Pluristem plans for human studies to begin in early 2009.
PLX-BMT Pluristem’s second product, targets an annual $2 billion market and is intended to resolve the global shortfall of matched hematopoietic stem cells (HSCs) for bone marrow transplantation (BMT). Approximately 60% of the 150,000 patients diagnosed annually with leukemia and other hematological malignancies are unable to find a suitable bone marrow donor match and are left with no reasonable therapeutic alternatives. In animals PLX-BMT, combined with the HSCs found in umbilical cord blood (UCB), has been shown to significantly increase the engraftment of these HSCs in bone marrow. Therefore, Pluristem believes it has potentially found an alternative to bone marrow transplantation by using UCB with PLX-BMT, an off-the-shelf product that requires no matching. Pluristem expects human trials to begin in early 2009.
Pluristem’s pipeline of products begins as adherent stromal cells (ASCs) that are derived from the human placenta, an organ that has traditionally been considered medical waste after childbirth and a non-embryonic, non-controversial source of cells. Pluristem’s placental-derived ASCs are then grown in a unique and proprietary three-dimensional (3D) microenvironment, termed the Pluristem PluriX™
3D bioreactor, without the addition of growth factors or other adulterants. The ASCs derived from this process are called PLacental eXpanded or PLX cells. Pluristem believes these cells' efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, these PLX cells are immune-privileged and possess immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations. The PLX cells are stored “ready to use” with no histocompatibility matching required.
Pluristem is an American public company the Company has an office in Colorado with headquarters housing its research and development and FDA good manufacturing practices (GMP)-approved facilities in Haifa, Israel.
Pluristem’s PLX Cells Show a Statistically Significant Advantage in a Pre-Clinical Study in the Multiple Sclerosis
NEW YORK–(BUSINESS WIRE)—
https://scamparoo.wordpress.com/2008/04/25/pre-clinical-study-in-ms-model-significant/
Your half way there !
No Deal, No Agenda, On No One's Mind
And many more will likely die because the original trials were too restrictive! Only 100 to be treated in EAP. There are MILLIONS of these suffering patients. VERY unfortunate that the trials didn't progress faster and the 'SAME' results for PAD seen in 2013/2014 didn't result in better designed trials addressing AMPUTATION!!! Thus, another 2 years for patient to suffer.
[color=red][/color]
Auto1
Wednesday, 09/19/18 09:51:22 AM
Re: FDApproved post# 15700
0
Post # of 16952
Nope... Now that they have finally gotten the right primary endpoint, Reductions in Amputations, it will take the full 2 years of follow up to get that indication.
That's the agreement wiyh the FDA. In Exchange due the small sample size... Look it up!
2020 earliest.
I present.... Your Leader
PLX-11
Thursday, 09/20/18 03:02:24 PM
Re: FDApproved post# 15766
0
Post # of 16951
EAP is done outside of the phase III clinical trial.
http://www.pluristem.com/wp-content/uploads/2018/01/Expanded_Access_Program_CLI_final_isa.pdf
"As part of the program, Pluristem’s PLX-PAD cell therapy will be made available to a limited number of Rutherford Category 5 CLI patients in the U.S. who are unsuitable for revascularization and cannot take part in the Company’s ongoing Phase III clinical study"
Clearly, they are being careful with the EAP. Probably a wise decision. Any added risk would not be worth the short term revenue gained.
Instead of paying for those that passed, let's pray for those that will be treated.
P$TI has quite a history of treating patients with early access, aka compassionate use, claiming 'miracles', only to have the patients die...
Do your research on psti and compassionate use.
Glass lifted. Welcome home!
Monday came and went, as well Tuesday, Wednesday, Thursday & Friday. No news, no deals, no Roctober.
Just the same old scam, just with two overpaid CEOs instead of one. This joke of a tiny blip of a company needing such a structure is laughable. We've gotten NOTHING for our money.
Now it looks clearly like we will fall well below $1.00, on our way back to the pink sheets.
Why is there no mention of PSTI?
Maybe, just maybe... Psssssst….. It has NOTHING to do with PSTI?!?!?!?!
This Probably Is What The BARDA DEAL WAS FOR !
'Counpound'.... Gheesh. Do you think J&J, BARDA etal. know the differences between 'counpounds', MABs, Cell-based Therapies, Small Molecules Protein Based Therapies, etc.?
Why can't it be exactly as they say? A compound??????
Only That Janssen Sits On The ARM BoD With Zami !
Wow!! That is quite the deduction to arrive at a partnership announcement on Monday. WHY didn't WE ALL see this in the 'tea leaves'?
More like 'bud leaves'